0.02
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Neurotech International
Its shares trade on ASX under the ticker NTI.AX. It has been listed since 4 November 2016. In the fiscal year to 30 June 2025, it reported revenue of A$2.4m and a net loss of A$10.6m. At that date it held total assets of A$3.2m and shareholders' equity of A$3.0m.
Neurotech International Ltd. engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2016-11-04. The firm is focused on the development and commercialization of neurological solutions focused predominately on pediatric neurological disorders. The firm conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its NTI/Dolce cannabis strains. The company is also commercializing Mente, a home therapy to increase engagement and improve relaxation in autistic children with elevated delta-band brain activity. Its product, Mente Autism, assists with the management of children with autism spectrum disorder (ASD). Its development program NTI164 completed a Phase I/II clinical trial to treat patients with autism spectrum disorder (ASD). Mente Autism is a portable, electroencephalographic (EEG) medical device for home use in the form of a headband that uses closed-loop neurofeedback to helo-relax the minds of children with ASD.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 4 Nov 2016
- Website
- neurotechinternational.com ↗
Leadership
Pay as last reported
- Mr. Mark DaviesNon-Executive Chairman of the BoardA$40,000
- Dr. Anthony FilippisChief Executive Officer, Managing Director, Executive Director, since 2024
- Dr. Alexandra AndrewsChief Operating OfficerA$145,226
- Mr. Gerald QuigleyDirector of Public Relations, Non-Executive Director, since 2022
- Assoc. Prof. Carolyn EllawayChief Medical Officer
- Ms. Alessandra GauvinCompany Secretary
- Mr. Robert JohnstonNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Neurotech International Ltd. focuses on pediatric neurological disorders in Australia.
- Mente Autism is a portable EEG device for home use in ASD management.
- NTI164 completed Phase I/II clinical trials for autism treatment.
Weaknesses
- The company's clinical studies assess cannabis strains for neurological solutions.
- Mente Autism targets children with elevated delta-band brain activity.
- Neurotech's commercialization is limited to Australia's Health Care sector.
Opportunities
- Neurotech's NTI/Dolce cannabis strains could expand neurological solution markets.
- Mente Autism's home therapy model offers scalable solutions for ASD.
- The firm's clinical trials may lead to new neurological treatment approvals.
Threats
- Neurotech's focus on pediatric neurological disorders limits market diversity.
- The company's reliance on cannabis strains for neurological solutions faces regulatory scrutiny.
- Mente Autism's target audience is restricted to children with ASD in Australia.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.